Our programs are organized around biological choke points

Conventional drug discovery organizes around indications: one disease, one program, one molecule, one development arc. 

Model Medicines engineers first-in-category, pipeline-in-a-pill therapeutics against biological choke points. These biological choke points represent targets that are structurally conserved, functionally essential, disease-driving, and offer multi-indication impact.

Our work demonstrates how large-scale computation can uncover entirely new classes of drugs once thought unreachable.